Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro, Mark Middleton, Simon R. Lord, Hendrik Tobias Arkenau, Andrew Tutt, Vandana Abramson, Emma Dean, Tufia C. Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer
Funding Information:
The authors would like to thank patients, investigators, co-investigators, and the study teams at each of the participating centers and at the healthcare business of Merck KGaA, Darmstadt, Germany. The authors thank Vertex Pharmaceuticals for their involvement in the development of berzosertib (formerly M6620, VX-970). Giuseppe Locatelli, PhD, an employee of the healthcare business of Merck KGaA, Darmstadt, Germany, contributed to the analysis and interpretation of the biomarker results. Bart Hendriks, PhD, a former employee of the healthcare business of Merck KGaA, Darmstadt, Germany, contributed to the analysis and interpretation of PK data. Annick Seithel-Keuth, PhD, an employee of the healthcare business of Merck KGaA, Darmstadt, Germany, contributed to the analysis and interpretation of PK data. Danyi Wang, MD, PhD, an employee of EMD Serono, Billerica, MA, USA, provided technical and operational support of biomarker sample analysis. Medical writing assistance was provided by Alexander T. Hardy of Bioscript Stirling Ltd, Macclesfield, UK and funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: https://doi.org/10.13039/100009945 ). The trial (including acquisition of data; analysis and interpretation of data; study supervision, conception, and design; development of methodology; administrative, technical or material support; and writing, review, and/or revision of the manuscript) was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany and Vertex Pharmaceuticals Incorporated., Boston, MA, USA.
Funding Information:
The authors would like to thank patients, investigators, co-investigators, and the study teams at each of the participating centers and at the healthcare business of Merck KGaA, Darmstadt, Germany. The authors thank Vertex Pharmaceuticals for their involvement in the development of berzosertib (formerly M6620, VX-970). Giuseppe Locatelli, PhD, an employee of the healthcare business of Merck KGaA, Darmstadt, Germany, contributed to the analysis and interpretation of the biomarker results. Bart Hendriks, PhD, a former employee of the healthcare business of Merck KGaA, Darmstadt, Germany, contributed to the analysis and interpretation of PK data. Annick Seithel-Keuth, PhD, an employee of the healthcare business of Merck KGaA, Darmstadt, Germany, contributed to the analysis and interpretation of PK data. Danyi Wang, MD, PhD, an employee of EMD Serono, Billerica, MA, USA, provided technical and operational support of biomarker sample analysis. Medical writing assistance was provided by Alexander T. Hardy of Bioscript Stirling Ltd, Macclesfield, UK and funded by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: https://doi.org/10.13039/100009945). The trial (including acquisition of data; analysis and interpretation of data; study supervision, conception, and design; development of methodology; administrative, technical or material support; and writing, review, and/or revision of the manuscript) was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany and Vertex Pharmaceuticals Incorporated., Boston, MA, USA.
Publisher Copyright:
© 2022, The Author(s).